CKD Summit 2022 March 1 - 3rd, 2022 | Boston, MA

Connect with George Clinical Renal Leaders at CKD.


The 4th Chronic Kidney Disease Drug Development Summit provides the opportunity to connect with renal leaders. The event is dedicated to accelerating the frontier of preventative and regenerative therapies to meaningfully target kidney disease and enlighten opportunities for indication expansion into rare renal disorders.

Will you be attending? If so, reach out to Matthew Reabold at [email protected] to discuss and/or schedule a time to meet with our scientific leaders. 

Three members of George Clinicals kidney and metabolic scientific leadership team will be in attendance: Hiddo Heerspink, Jonathan Barrett and Roberto Pecoits-Filho.

Professor Barrett will be presenting on Tuesday,  March 1st from  3-6 pm on Elucidating the Pathogenesis of IgA Nephropathy & Learning from Clinical Updates to Identify Potential Therapeutic Targets in IgAN.

Professor Heerspink will be presenting on Wednesday, March 2nd during two sessions:

  • 8 am Panel Discussion: How Can We Modernize Surrogate Endpoint Development? Moving Beyond Hard Endpoints
  • 9 am Presentation: Examining the Validity & Practical Implications of eGFR Change & Albuminuria as Surrogate Endpoints of Kidney Failure

In addition, this year’s event provides the opportunity to hear from industry leaders that will share their expertise and cover topics including:

  • Evaluating Surrogate Endpoints to Accelerate Clinical Trials & Drive Innovation
  • Patients, Trials & Endpoints: Pivoting to Rare Kidney Diseases to Meet Significant Unmet Medical Need
  • What Is the Next Step After SGLT2 Inhibitors? Complementing the New Standard of Care
  • Confronting Patient Recruitment: How can we get the Right Patients into Trials?

 

 

George Clinical's Leadership in Attendance

Professor Heerspink’s principal research interests include optimizing current treatment strategies and finding new therapeutic approaches to halt the progression of renal and cardiovascular disease in patients with diabetes with a specific focus on personalized medicine. He is Professor of Clinical Trials and Personalized Medicine; Clinical Pharmacologist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen, the Netherlands; and visiting professor at the University of New South Wales in Sydney. He worked as a Postdoctoral Fellow at The George Institute for Global Health, Sydney, Australia, where he investigated the effects of blood pressure-lowering regimens on renal and cardiovascular outcomes in patients with chronic kidney disease.

Professor Heerspink leads and participates in clinical trials focused on renal and cardiovascular complications of Type 2 diabetes. His main expertise includes clinical trial design and personalized medicine as well as methodological aspects and statistical analyses of clinical trials. Based on his work at The George Institute, he was awarded a young investigator grant and subsequently in 2015 a consolidator investigator grant from the Dutch organization of scientific research and received in 2016 the Galien award for his research. 

Professor Barratt’s research is focused on pathogenesis of IgA nephropathy and a range of areas across renal medicine including glomerular disease, multi-system renal disease and complications of chronic kidney disease, in particular renal associated anaemia. He is the IgA nephropathy Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases and leads the Renal Research Group within the College of Life Sciences, University of Leicester. He also participates in other IgA nephrology  initiatives such as the International IgA Nephropathy Network and in workgroups identifying endpoints for clinical trials such as the FDA and ASN Kidney Health Initiative.

Professor Barratt has been Principal Investigator for international randomized controlled clinical trials in IgA nephropathy and has attended both the FDA and EMA as an expert witness for new therapies in IgA nephropathy. He is an Editorial Board member for Kidney International and Clinical Journal of the American Society of Nephrology and sits on the Kidney Research UK Grants committee. 

Roberto Pecoits-Filho, MD, PhD, FACP, FASN

  • Professor of Nephrology at the School of Medicine, Catholic University of Paraná State in Brazil, Senior Research Scientist, Arbor Research Collaborative for Health in the USA

Dr. Pecoits-Filho’s research is focused on chronic kidney disease and he is currently a Visiting Researcher at The George Institute for Global Health, Sydney. He was a member of the Executive Committee of KDIGO and the International Society of Nephrology (ISN) and is currently the chair of the ISN Education Working Group, and part of the Core Group of ISN’s Advancing Clinical Trials Initiative. He is Senior Research Scientist at Arbor Research collaborative for Health; Professor of Medicine at the Pontifical Catholic University of Paraná in Brazil; and a practicing nephrologist.

Dr. Pecoits-Filhoh has played an active role in study design, implementation, coordination, event adjudication, data management and data monitoring safety for various trials. His participation in clinical trials includes as Principal Investigator, National Leader and Chair or member of steering committees. He has been featured in a series of ISN podcasts covering the diverse topics related to the field of nephrology and current issues that impact nephrologists around the world.

Event Location

Hyatt Regency Boston
1 Ave de Lafayette
Boston, MA
USA

Attending this event?

Meet with George Clinical! Contact us to schedule a time now.

    I agree to the handling of my personal information in accordance with the George Clinical privacy policy.

    Please input this code: captcha

    Add George Clinical to your network